Amylyx Pharmaceuticals, INC

Amylyx Pharmaceuticals announced a material definitive agreement for a stock offering, securing approximately $471.7 million in net proceeds.

Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia, meeting all primary and secondary endpoints.

Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia, meeting primary and secondary endpoints.

Amylyx Pharmaceuticals reported Q2 2026 financial results, highlighting the completion of patient visits for the pivotal Phase 3 LUCIDITY trial of avexitide, with topline data expected in late August or early September 2026.

Amylyx Pharmaceuticals stockholders approved director elections, ratified auditor appointment, and advisory compensation at the June 4, 2026 Annual Meeting.

Amylyx Pharmaceuticals reported Q1 2026 financial results, highlighting progress in its Phase 3 LUCIDITY trial for avexitide with topline data anticipated in Q3 2026 and a cash runway extending into 2028.

Amylyx Pharmaceuticals details Q2 2026 financial performance, highlighting increased R&D and SG&A expenses, while advancing its pipeline candidates avexitide and AMX0035.

Amylyx Pharmaceuticals reports increased R&D spending and a net loss for Q1 2026, with cash reserves projected to last into 2028.

Amylyx Pharmaceuticals reports Q3 2025 results, highlighting a strategic pivot to its pipeline assets, avexitide, AMX0035, and AMX0114, following the discontinuation of RELYVRIO/ALBRIOZA.

Amylyx Pharmaceuticals reports significant losses following the discontinuation of its lead commercial product, RELYVRIO, while advancing new investigational therapies with positive early clinical data and securing fresh capital.

Amylyx Pharmaceuticals reports a net loss for Q1 2025 and focuses on advancing its pipeline following the discontinuation of RELYVRIO/ALBRIOZA.

Amylyx Pharmaceuticals reports a net loss for Q3 2024 and focuses on its pipeline after discontinuing its ALS drug, RELYVRIO/ALBRIOZA.

Amylyx Pharmaceuticals reports a strategic shift following the withdrawal of its ALS drug, focusing on a pipeline of novel therapies for endocrine and neurodegenerative diseases, supported by significant capital raises.

Amylyx Pharmaceuticals' 2024 10-K filing details a strategic pivot, emphasizing pipeline development after ceasing sales of RELYVRIO/ALBRIOZA, alongside financial results and future outlook.

Amylyx Pharmaceuticals generated $403 million in net product revenue in 2023 from its ALS treatments, RELYVRIO and ALBRIOZA, and is advancing clinical trials for other neurodegenerative diseases.

James M Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc., received 22,807 shares of common stock on August 18, 2026.

Justin B. Klee, Co-Chief Executive Officer and a Director of Amylyx Pharmaceuticals, Inc., received 60,039 shares of common stock on August 18, 2026.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc., received 21,284 shares of common stock on August 18, 2026.

Camille L Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, Inc., received 22,807 shares of common stock on August 18, 2026.

Joshua B Cohen, Co-Chief Executive Officer and a Director of Amylyx Pharmaceuticals, Inc., received 60,039 shares of common stock on August 18, 2026.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc., sold 30,000 shares of common stock on July 9, 2026.

Amylyx Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 4, 2026, focusing on director elections, auditor ratification, and executive compensation.

Amylyx Pharmaceuticals will hold its annual stockholder meeting virtually on June 5, 2025, to vote on director elections, auditor ratification, and executive compensation.

Amylyx Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Amylyx Pharmaceuticals announces its annual stockholder meeting to be held virtually on June 6, 2024, with proxy materials available online.

Amylyx Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Perceptive Advisors LLC and Joseph Edelman have reported a 7.5% beneficial ownership stake in Amylyx Pharmaceuticals, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Amylyx Pharmaceuticals Inc. following an internal realignment.

Adage Capital Management and its principals have reduced their beneficial ownership in Amylyx Pharmaceuticals, Inc. to 2.53%.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 15.0% beneficial ownership stake in Amylyx Pharmaceuticals Inc. common stock as of December 31, 2025.

The Vanguard Group has reported a 5.28% beneficial ownership stake in Amylyx Pharmaceuticals Inc., holding 5,804,912 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2025.